Chemed Co. (NYSE:CHE) CEO Kevin J. Mcnamara Sells 4,000 Shares

Chemed Co. (NYSE:CHEGet Free Report) CEO Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $567.54, for a total value of $2,270,160.00. Following the completion of the sale, the chief executive officer now owns 108,549 shares in the company, valued at $61,605,899.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Chemed Stock Down 0.6 %

Shares of Chemed stock opened at $565.23 on Friday. The stock has a market cap of $8.56 billion, a P/E ratio of 30.42, a P/E/G ratio of 2.32 and a beta of 0.46. Chemed Co. has a 12-month low of $492.84 and a 12-month high of $654.62. The business’s 50 day moving average is $609.73 and its 200-day moving average is $595.68.

Chemed (NYSE:CHEGet Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The company reported $4.68 EPS for the quarter, missing analysts’ consensus estimates of $5.09 by ($0.41). The firm had revenue of $589.23 million during the quarter, compared to the consensus estimate of $587.18 million. Chemed had a net margin of 12.36% and a return on equity of 30.52%. On average, sell-side analysts expect that Chemed Co. will post 21.72 EPS for the current year.

Institutional Trading of Chemed

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rise Advisors LLC bought a new stake in Chemed in the 1st quarter valued at $26,000. GAMMA Investing LLC acquired a new position in Chemed in the 4th quarter valued at about $37,000. Larson Financial Group LLC bought a new position in Chemed in the 3rd quarter valued at about $44,000. Principal Securities Inc. acquired a new stake in Chemed during the fourth quarter worth approximately $51,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of Chemed by 110.6% during the fourth quarter. SRS Capital Advisors Inc. now owns 99 shares of the company’s stock worth $58,000 after acquiring an additional 52 shares during the period. Institutional investors own 95.85% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. StockNews.com raised Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Oppenheimer raised their target price on shares of Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, Royal Bank of Canada increased their price objective on shares of Chemed from $604.00 to $712.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th.

View Our Latest Report on CHE

About Chemed

(Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Recommended Stories

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.